Solar Panels for
Pharmaceutical Plants
GMP Compliant Installations

Yes. Pharmaceutical solar installations are designed to meet GMP requirements under EU GMP Chapter 3 (Premises and Equipment) and MHRA standards. All installation procedures maintain clean room integrity through validated materials, sealed work areas, and continuous particle monitoring. Full IQ/OQ/PQ documentation is provided for regulatory audit. Zero contamination incidents across all pharmaceutical installations.

The revised EU GMP Annex 1 (August 2023 implementation) requires sterile manufacturers to maintain a documented Contamination Control Strategy (CCS). Any facility modification — including rooftop solar — must be formally assessed against this CCS. Our pre-installation process includes a CCS gap analysis, formal change control submission, pre-works particle baseline measurement per ISO 14644-2, and post-installation requalification sampling. All records are provided in MHRA audit-ready format.

Solar systems power pharmaceutical HVAC loads during daylight hours, with grid electricity maintaining operations overnight and on low-irradiance days. Systems are sized for continuous HVAC loads — clean room air handling (ISO 5-8 classifications), temperature/humidity control, and HEPA filtration. The grid connection is maintained as primary supply; solar provides offset rather than primary power, ensuring no risk to critical environmental controls. Typical 500kW–1MW installations offset 40–60% of annual HVAC energy costs.

Full IQ/OQ/PQ documentation is provided. Installation Qualification (IQ) covers design specification, component traceability, and calibration records to BS EN 62446-1:2016. Operational Qualification (OQ) covers grid connection commissioning per G99 and inverter performance verification. Performance Qualification (PQ) covers a 90-day monitored performance period with half-hourly generation data. All computerised systems are documented per GAMP 5 guidelines. Documentation is provided within 10 working days of commissioning.

Most large pharmaceutical manufacturers qualify under ESOS Phase 4 (qualification date: 31 December 2026). Installing solar before this date reduces your measured energy consumption baseline, which can affect the scale of required ESOS action plan measures. Half-hourly metering data from the solar system satisfies ESOS evidence requirements for your lead energy assessor. We recommend reading our full ESOS Phase 4 solar compliance guide for detailed guidance.

Solar panels are classified as special rate assets under s.104A Capital Allowances Act 2001 (HMRC CA23153). The primary relief is Annual Investment Allowance (AIA): 100% first-year deduction on the first £1 million of qualifying expenditure per tax year. For systems exceeding £1M, the 50% First Year Allowance (FYA, made permanent in Autumn 2023) applies to the excess. Full expensing does not apply to solar. See our detailed capital allowances guide for worked examples with your system size.